EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Development of a Synthetic Lethality‐Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate Cancer

Masaru Tani iD, Koji Hatano iD, Yu Ishizuya, Toshiki Oka iD, Tomohiro Kanaki, Shunsuke Inoguchi, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Sassi Nesrine, Yohei Okuda, Akinaru Yamamoto iD und 11 weitere

Cancer Science · 2025-12 · 116 (12) · 3403-3416

DOI: 10.1111/cas.70194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 16.09.2025. Verfasst von Masaru Tani und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The University of Osaka Graduate School of Medicine, Suita, Japan. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Synthetic Lethal Mutations, DNA Ligase ATP, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in androgen receptor signaling inhibitors (ARSIs) and poly (ADP‐ribose) polymerase inhibitors (PARPIs), metastatic castration‐resistant prostate cancer (mCRPC) remains lethal. PARPIs clinical efficacy is limited in patients with homologous recombination repair deficiencies, such as BRCA1/2 mutations, due to resistance. Thus, identifying novel synthetic lethal interactions with PARP may expand treatment options and improve therapeutic efficacy. Here, to identify genes that influence sensitivity to the PARPI olaparib, we conducted a genome‐wide CRISPR‐Cas9 knockout screening of 18,010 genes in DU145, 22Rv1, and LNCaP prostate cancer cell lines. Our screening identified PARP and LIG1 as synthetic lethality‐inducing factors, whereas TP53 conferred resistance to PARPIs. Simultaneous inhibition of LIG1 and PARP increased DNA damage and apoptosis. Additionally, the combination of the LIG1 inhibitor L82‐G17 with olaparib exhibited synergistic effects. To the best of our knowledge, we validated this combination therapy in vivo for the first time, suppressing tumor growth in a DU145 xenograft model while minimizing toxicity in normal tissues. Immunohistochemical analysis revealed that LIG1 was overexpressed in CRPC tissues, suggesting its potential as a therapeutic target. This study established LIG1 as a novel synthetic lethality‐inducing factor in prostate cancer, showing that L82‐G17 enhances the efficacy of olaparib, regardless of the BRCA mutation status. These findings suggest that the combination of PARP and LIG1 inhibitors could be a novel therapeutic strategy for mCRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsSynthetic Lethal MutationsDNA Ligase ATPProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAnimalsCell Line, TumorMicePhthalazinesPiperazinesXenograft Model Antitumor AssaysApoptosisDNA DamageDrug SynergismDrug Resistance, NeoplasmCRISPR-Cas SystemsMice, NudeTumor Suppressor Protein p53

Stichwörter der Autor:innen

CRISPR‐Cas9 knockout screeningLIG1 inhibitorsPARP inhibitorprostate cancersynthetic lethality

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsolaparibPhthalazinesPiperazinesDNA Ligase ATPTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Urology, The University of Osaka Graduate School of Medicine, Suita, Japan.
  • Graduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Japan.
  • Stem Cell Genetics, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Division of Gene Therapy Science, Gunma University Initiative for Advanced Research, Gunma University, Maebashi, Japan.

ORCID-Profile: Masaru Tani, Koji Hatano, Toshiki Oka, Akinaru Yamamoto, Taigo Kato, Atsunari Kawashima, Norio Nonomura

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Tani, M., Hatano, K., Ishizuya, Y., Oka, T., Kanaki, T., Inoguchi, S., Yoshimura, A., Horibe, Y., Liu, Y., Nesrine, S., Okuda, Y., Yamamoto, A., Uemura, T., Yamamichi, G., Hayashi, T., Yamamoto, Y., Kato, T., Kawashima, A., Yamaguchi, T., …, & Nimura, K. (2025). Development of a Synthetic Lethality‐Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate Cancer. Cancer Science, 116(12), 3403-3416. https://doi.org/10.1111/cas.70194

Vancouver

Tani M, Hatano K, Ishizuya Y, Oka T, Kanaki T, Inoguchi S, et al. Development of a Synthetic Lethality‐Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate Cancer. Cancer Science. 2025;116(12):3403-3416. doi:10.1111/cas.70194

BibTeX
@article{Tani2025,
  author = {Tani, Masaru and Hatano, Koji and Ishizuya, Yu and Oka, Toshiki and Kanaki, Tomohiro and Inoguchi, Shunsuke and Yoshimura, Akihiro and Horibe, Yuki and Liu, Yutong and Nesrine, Sassi and Okuda, Yohei and Yamamoto, Akinaru and Uemura, Toshihiro and Yamamichi, Gaku and Hayashi, Takuji and Yamamoto, Yoshiyuki and Kato, Taigo and Kawashima, Atsunari and Yamaguchi, Takao and Obika, Satoshi and Yusa, Kosuke and Nonomura, Norio and Nimura, Keisuke},
  title = {Development of a Synthetic Lethality‐Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate Cancer},
  journal = {Cancer Science},
  year = {2025},
  volume = {116},
  number = {12},
  pages = {3403--3416},
  doi = {10.1111/cas.70194}
}
Kostenlos starten →